Last reviewed · How we verify
GW642444 Inhalation Powder
GW642444 is a long-acting beta-2 adrenergic receptor agonist that relaxes airway smooth muscle to improve airflow in respiratory diseases.
GW642444 is a long-acting beta-2 adrenergic receptor agonist that relaxes airway smooth muscle to improve airflow in respiratory diseases. Used for Chronic obstructive pulmonary disease (COPD), Asthma.
At a glance
| Generic name | GW642444 Inhalation Powder |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
As a beta-2 agonist, GW642444 binds to beta-2 adrenergic receptors on airway smooth muscle cells, triggering a cascade that increases intracellular cAMP and causes bronchodilation. The inhalation powder formulation delivers the drug directly to the lungs for rapid local effect. Long-acting formulations like this are designed to provide sustained bronchodilation over 12-24 hours, reducing the need for frequent dosing.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
- Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma (PHASE3)
- An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma (PHASE3)
- A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma (PHASE3)
- A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD (PHASE3)
- A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW642444 Inhalation Powder CI brief — competitive landscape report
- GW642444 Inhalation Powder updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI